Horm Metab Res 2011; 43(10): 728-730
DOI: 10.1055/s-0031-1285868
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Thyroglobulin and Thyroglobulin Autoantibodies Measurement Using the Automated KRYPTOR® Platform in Patients with Differentiated Thyroid Carcinoma

L. Giovanella*
1   Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
2   Department of Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
,
E. Toffalori*
3   Department of Laboratory Medicine, APSS Provincia Autonoma di Trento, Trento, Italy
,
L. Ceriani
1   Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
,
M. Caputo*
4   Department of Clinical Chemistry and Microbiology, ULSS 12 Regione Veneto, Bussolengo, Italy
,
F. Verburg
5   Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany
› Author Affiliations
Further Information

Publication History

received17 May 2011

accepted 19 July 2011

Publication Date:
19 September 2011 (online)

Abstract

The aim of the present study is 1) to compare our established manual thyroglobulin (Tg) and Tg autoantibody (TgAb) immunoassays to the automated KRYPTOR® platform from the same manufacturer, in a large group of DTC patients and 2) to evaluate whether a change in assay methods could be made without disrupting the serial monitoring pattern. Sera from 160 patients with histologically proven DTC were obtained and Tg and TgAb measured by manual immunoassays and a fully automated platform. We found an excellent agreement between the 2 methods for Tg measurement (R=0.9888, p<0.00001) with a 90% overall concordance rate. At the same time, a weak relationship was found between the two methods for TgAb measurement (R=0.4438, p<0.03). However, 151 patients had concordant results with a 94% overall concordance rate. In conclusion, the excellent correlation we found between the Tg assays make the fully automated KRYPTOR® Tg assay interchangeable with the established Dyno-test® Tg-plus in patients with DTC. A very high qualitative concordance rate was found between Dyno-test® TgAbn and KRYPTOR® TgAb assays, making these methods interchangeable to screen sera for the presence of TgAb. However, since quantitative discordances still occurred in some patients a re-baseline of TgAb positive patients is strongly supported before changing the TgAb assay method.

*

* Members of the Endocrinology and Metabolism Study Group of Italian Society of Laboratory Medicine (SIMeL).


 
  • References

  • 1 Grebe SKG. Expert Rev Endocrinol Metab 2009; 4: 25-43
  • 2 Verburg FA, Waschle K, Reiners C, Giovanella L, Lentjes EG. Horm Metab Res 2010; 42: 736-773
  • 3 Spencer CA. J Clin Endocrinol Metab 2005; 90: 5566-5575
  • 4 Demers CM, Spencer CA. Thyroid 2003; 13: 3-126
  • 5 Mathis G. Clin Chem 1993; 39: 1953-1059
  • 6 Krahn J, Dembinski T. Clin Biochem 2009; 42: 416-419
  • 7 Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussière F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou EJ. Clin Endocrinol Metab 2007; 92: 2487-2495
  • 8 Giovanella L, Maffioli M, Ceriani L, De Palma D, Spriano G. Clin Chem Lab Med 2009; 47: 1001-1004
  • 9 Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romin JA, Smit JW. Clin Endocrinol 2007; 66: 58-64
  • 10 Spencer C, Petrovic I, Fatemi S. J Clin Endocrinol Metab 2011; 96: 1283-1291